Boston Scientific slides after quarterly sales of key products disappoint

Shares of medical device maker Boston Scientific BSX.N tumble 10% to $82.65 premarket

BSX expects 2026 adjusted EPS of $3.43 to $3.49, the midpoint of which is below analysts' average estimate of $3.47 - LSEG-compiled data

Estimates net sales growth between 10.5% and 11.5% for 2026, slower than its 19.9% growth in 2025

Electrophysiology franchise (EP) sales of $890 million below Street estimates of $933 million, according to RBC analysts

Sales of Watchman, co's stroke prevention device, came in 1% below consensus with U.S. market entirely responsible for the miss, at least three analysts said

"Investors now have reason to question the trajectory of these two key growth drivers moving forward" - brokerage J.P. Morgan, referring to EP and Watchman businesses

BSX reports Q4 EPS of 80 cents vs. average estimate of 78 cents

Posts Q4 revenue of $5.29 billion vs. average estimate of $5.28 billion

Shares fell ~7% in 2025